

Nishit B Modi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4842926/nishit-b-modi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

1,677
citations

21
h-index

40
g-index

60
ext. papers

1,805
ext. citations

3.8
avg, IF

4.03
L-index

#	Paper	IF	Citations
54	Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations. <i>Clinical Neuropharmacology</i> , 2019 , 42, 149-156	1.4	4
53	Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules. <i>Clinical Neuropharmacology</i> , 2019 , 42, 4-8	1.4	5
52	Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 839-845	3.1	8
51	Pharmacokinetics of Rytary, An Extended-Release Capsule Formulation of Carbidopa-Levodopa. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 999-1014	6.2	24
50	Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation. <i>AAPS Journal</i> , 2017 , 19, 607-618	3.7	4
49	Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers. <i>Xenobiotica</i> , 2016 , 46, 1001-16	2	5
48	Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 974-82	2.9	9
47	Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers. <i>Clinical Neuropharmacology</i> , 2016 , 39, 10-7	1.4	17
46	Pharmacokinetics, distribution, metabolism, and excretion of the dual reuptake inhibitor [(14)C]-nefopam in rats. <i>Xenobiotica</i> , 2016 , 46, 1026-48	2	1
45	Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®). <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 995-1003	2.9	48
44	Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 837-45	5.3	19
43	Recombinant Coagulation Factors and Thrombolytic Agents 2013 , 299-320		
42	Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 523-31	2.9	21
41	Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2246-52	7	77
40	Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 634-42	2.9	17
39	Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 607-14	3.5	15
38	Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 315-22	2.9	15

37	Dapoxetine and paroxetine for the treatment of premature ejaculation. <i>Clinical Neuropharmacology</i> , 2007 , 30, 315	1.4	1
36	Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007 , 17, 153-64	2.9	54
35	Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1023-9	2.9	34
34	Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 301-9	2.9	100
33	Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 919-26	2.9	6
32	Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 31-40	6.1	40
31	Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. <i>Archives of General Psychiatry</i> , 2003 , 60, 204-11		201
30	Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. <i>Biopharmaceutics and Drug Disposition</i> , 2002 , 23, 17-31	1.7	7
29	Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 1229-45	6.2	122
28	Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2437-45	5.6	41
27	Pharmacokinetics and pharmacodynamics of sibraxifiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 488-95	2.9	4
26	Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 508-15	2.9	30
25	Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications. <i>Biopharmaceutics and Drug Disposition</i> , 2000 , 21, 321-6	1.7	32
24	Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. <i>Biopharmaceutics and Drug Disposition</i> , 2000 , 21, 23-31	1.7	43
23	Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 379-88	2.9	83
22	Pharmacokinetics and pharmacodynamics of sibraxifiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 675-84	2.9	8
21	Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens. <i>Biopharmaceutics and Drug Disposition</i> , 1998 , 19, 31-8	1.7	10
20	Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 169-176	7	29

19	Pharmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant, TNK-tPA, in Patients with Acute Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 134-139	7	64
18	Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, 397-405	3.1	4
17	Determination of Ro 48-3656 in rat plasma by reversed-phase high-performance liquid chromatography. Comparison of 1.5-microm nonporous silica to 3.5-microm porous silica analytical columns. <i>Biomedical Applications</i> , 1997 , 704, 231-42		8
16	TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. <i>Circulation</i> , 1997 , 95, 351-6	16.7	176
15	Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. <i>Journal of Medicinal Chemistry</i> , 1996 , 39, 3139-47	8.3	108
14	Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIb/IIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 27, 105-12	3.1	3
13	Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIb/IIIa antagonist, in rats and dogs. <i>Journal of Cardiovascular Pharmacology</i> , 1995 , 25, 888-97	3.1	15
12	Application of a variable direction hysteresis minimization approach in describing the central nervous system pharmacodynamic effects of alfentanil in rabbits. <i>Journal of Pharmaceutical Sciences</i> , 1994 , 83, 351-6	3.9	3
11	Pharmacokinetics and pharmacodynamics of recombinant proteins and peptides. <i>Journal of Controlled Release</i> , 1994 , 29, 269-281	11.7	14
10	Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil. <i>Pharmaceutical Research</i> , 1994 , 11, 128-35	4.5	2
9	Phenobarbital removal characteristics of three brands of activated charcoals: a system analysis approach. <i>Pharmaceutical Research</i> , 1994 , 11, 318-23	4.5	5
8	A system approach to pharmacodynamics. Input-effect control system analysis of central nervous system effect of alfentanil. <i>Journal of Pharmaceutical Sciences</i> , 1993 , 82, 266-72	3.9	16
7	Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nifedipine hydrochloride in healthy males. <i>Journal of Pharmaceutical Sciences</i> , 1993 , 82, 705-13	3.9	3
6	A system approach to pharmacodynamics. Plasma iron mobilization by endogenous erythropoietin in the sheep fetus; evidence of threshold response in spontaneous hypoxemia. <i>Journal of Pharmaceutical Sciences</i> , 1993 , 82, 804-7	3.9	4
5	Application of neural networks to pharmacodynamics. <i>Journal of Pharmaceutical Sciences</i> , 1993 , 82, 918-36		44
4	Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992 , 20, 397-412; discussion 413-8		33
3	An algorithm for constrained deconvolution based on reparameterization. <i>Journal of Pharmaceutical Sciences</i> , 1992 , 81, 175-80	3.9	12
2	Pharmacodynamic system analysis of the biophase level predictor and the transduction function. <i>Journal of Pharmaceutical Sciences</i> , 1992 , 81, 925-34	3.9	14

- 1 Optimal extravascular dosing intervals. *Journal of Pharmacokinetics and Pharmacodynamics*, **1991**, 19, 405-12